Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin induction therapy dosing in kidney transplantation
ISRCTN17364752Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2013
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of antithymocyte globulin in graft rejection (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Rate and severity of acute rejection. Started Jan 2013; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
graft rejection
Beyond the preview
Go deeper on ISRCTN17364752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17364752.